undamentalytics Newsletter
Sign in

Innospec Inc. (IOSP) stock

Add to watchlist

Add holding +

NASDAQ: IOSP Nasdaq Specialty Chemicals Next results ~November 3, 2026

B Fundamentals grade

Innospec Inc. is a US-listed company in the specialty chemicals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$79

Cash-flow model

Base case. Range ~$62–$100 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 27% above our base value.

Price used: $100.72, November 3, 2026

Innospec Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 18 sales by directors and officers, last 12 monthsInsider trades
  • Funds143 adding, 123 cuttingOf 51 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Innospec files

Where Innospec stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.84bn, up 2.9% on a year earlier, faster than the 0.2% growth a quarter earlier. Free-cash-flow margin fell to 3.7% from 5.4% a year earlier. Operating margin narrowed to 7.0% from 9.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $76.54 a share, against a share price of $99.89. At that price, our model says the market is pricing in about 7.1% a year of cash-flow growth for five years, faster than the 4.4% a year revenue growth it has delivered.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Innospec Inc.'s trailing-twelve-month revenue grew 2.9% year on year, with a free-cash-flow margin of 3.7%.

Our discounted-cash-flow model values the business at ~$79 per share in the base case (~$62–$100 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 28.9% while net income grew 529.5%: a 558pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 1.1% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.3bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Priced above our value. The share price of $99.55 is 20% above our value per share of $79.
  • Weak cash conversion. Free cash flow was 57% of net income over the last 12 months.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$1.27 against an average estimate of $1.05: beat by 21.3%
Revenue
$491m, up 11.8% on a year earlier
Share reaction
+5.6% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 3, 2026; average EPS estimate $1.26

Innospec's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.2%
  • 1 week+0.8%
  • 1 month+3.4%
  • This year+31.6%
  • 1 year+40.1%
  • 5 years+20.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.8B
Operating margin
7.0%
Net margin
6.6%
EPS (TTM, diluted)
$4.89

Growth

Revenue growth
+2.9%
Change in growth rate
+2.6 pts
Share count change
−1.1%

Cash

Free cash flow (TTM)
$68.8M
FCF margin
3.7%
Stock pay % of revenue
0.6%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Innospec Inc. valuation models and calculator

What the price is pricing in

The share price implies about 7.4% a year of cash-flow growth for five years.That is close to the 4.4% a year revenue growth Innospec has delivered.

  • Priced in7.4%
  • Last 12 months2.9%
  • 3 years a year-2.9%
  • 5 years a year4.4%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($100.72, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$79
Price used
$100.72close November 3, 2026
Implied change
▼ 21%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Innospec Inc.'s free cash flow after stock-based pay with after-tax interest added back ($99.9M, FY2026 Q2 TTM), growing 4.6% and 2.9% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$62–~$100 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Innospec Inc.'s free cash flow after stock-based pay ( $99.9M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Innospec Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$79 ~$62–$100 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$88 ~$71–$110 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$58 ~$38–$91 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$59 ~$50–$71 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$73 ~$58–$88 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Innospec Inc. with Specialty Chemicals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −21%
  • Revenue growth 5 points higher ▲ +28%
  • Free-cash-flow margin 1 point lower ▼ −22%
  • Last year's free-cash-flow margin change, if it persists ▼ −27%
  • Discount rate 1 point higher ▼ −12%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $68$89$116$153$200$262
8.5% $54$69$89$115$149$193
10% $46$58$73$93$119$152

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$46.94$59.95$62.53$55.35$93.78$83.46$84.10$96.92$117.72$106.46$75.65$99.55
Market value$1.2bn$1.5bn$1.5bn$1.4bn$2.3bn$2.1bn$2.1bn$2.4bn$2.9bn$2.7bn$1.9bn$2.5bn
+ Net debt (− = net cash)−$5m$167m$128m$85m−$17m−$105m−$142m−$147m−$204m−$289m−$293m−$250m
Enterprise value$1.1bn$1.6bn$1.7bn$1.4bn$2.3bn$2.0bn$1.9bn$2.3bn$2.7bn$2.4bn$1.6bn$2.2bn
Multiples
Price / sales 1.1x1.7x1.2x0.9x1.5x1.7x1.4x1.2x1.5x1.4x1.1x1.3x
Price / earnings 9.7x18.0x24.8x16.0x20.7x72.1x22.5x18.2x21.2x75.1x16.2x20.4x
Price / free cash flow 11.5x16.5x25.8x17.9x17.6x17.8x38.6x57.5x20.3x18.7x21.5x35.9x
EV / EBITDA 6.0x12.0x9.5x7.9x11.7x24.6x11.1x10.0x13.6x10.8x9.2x13.0x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

62 /100

Moderate moat

How hard Innospec's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 12 / 20

    Cash operating profit has been a median 9.9% of total assets over 10 years.

  • Pricing power 11 / 20

    Gross margin has been a median 29.8%, moving by 1.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median 8.9%; its worst year was 5.0%.

  • Cash conversion 12 / 20

    Free cash flow was positive in 9 of 10 years, at a median 6.2% of revenue.

  • Discipline 17 / 20

    The diluted share count fell 0.1% over five years; stock-based pay has been a median 0.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $479m and EPS of $1.26 (range $1.24 to $1.29) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.92 −7% $1.9bn +7%
Next $6.17 +25% $2.0bn +6%

Next year's EPS estimate has moved +1.4% in 90 days, across 3 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.05 $1.27 +21.3%
Mar 2026 $1.01 $1.05 +3.5%
Dec 2025 $1.24 $1.50 +21.0%
Sept 2025 $1.06 $1.12 +5.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026

No numeric guidance in Innospec Inc.'s latest earnings release (filed August 5, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Innospec Inc.'s revenue by +4.6% next year and +2.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+6.4%, weight 60%) and the company's own record (+2.0%, weight 40%) . How the weights are set.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123
  3. Aug 2026123

Counts of recommendations published by analysts covering Innospec Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.8%
of tradable shares
Days to cover
2.35
at average volume
Short interest, 1 month
+5%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
1.3%
of shares
Employees
2,450
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +38.6%

$71.85 on October 31, 2025 to $99.55

ThenNowEffect
Revenue (last 12 months) $1.8bn $1.8bn +2.9%
Net margin 1.1% 6.6% +512.0%
P/E multiple 93.5x 20.4x −78.2%
Share count 25m 25m +1.1%

Biggest factor: net margin.

Last 3 years +4.5%

$95.22 on November 3, 2023 to $99.55

ThenNowEffect
Revenue (last 12 months) $2.0bn $1.8bn −8.5%
Net margin 6.3% 6.6% +5.2%
P/E multiple 18.8x 20.4x +8.1%
Share count 25m 25m +0.6%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IOSP+1%+15%+22%−10%−29%+32%
Industry peers (median)+19%−26%−9%+7%−13%+5%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IOSP50%58%50%42%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IOSP−22%−20%−19%−20%−38%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 48% from July 23, 2024 to March 20, 2026. Getting back needed a 94% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$65.12 – $101.41
From 52-week high
−1.8%
vs 50-day average
+3.5%
vs 200-day average
+18.4%
Volatility (1 year)
23%
Beta vs S&P 500
0.49

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±4.4%
After a week
8 up, 4 down
typical move ±6.3%
After a month
7 up, 5 down
typical move ±7.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +5.6% −0.4% +7.4% +7.4%
May 8, 2026 +5.5% +1.1% +2.0% +9.3%
February 18, 2026 −4.0% +0.2% −9.3% −22.0%
November 5, 2025 +1.7% −0.7% +3.6% +5.1%
August 6, 2025 −1.1% +0.7% +5.3% +6.2%
May 9, 2025 −2.9% +3.2% −4.7% −4.0%
February 19, 2025 −6.1% −0.2% −5.7% −10.4%
November 6, 2024 +8.0% +3.3% +9.6% +5.2%
August 7, 2024 −7.5% +1.6% −9.2% −9.9%
May 10, 2024 +2.1% +0.1% +3.1% −0.5%
February 14, 2024 +7.3% +1.6% +5.9% +4.3%
November 8, 2023 +1.5% −0.7% +9.8% +10.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Innospec Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 3, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Innospec Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Innospec Inc.
$1.8B $1.8B $1.9B $1.9B $2B $2B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $2B Revenue (TTM), FY23 Q4: $1.9B Revenue (TTM), FY24 Q1: $1.9B Revenue (TTM), FY24 Q2: $1.9B Revenue (TTM), FY24 Q3: $1.9B Revenue (TTM), FY24 Q4: $1.8B Revenue (TTM), FY25 Q1: $1.8B Revenue (TTM), FY25 Q2: $1.8B Revenue (TTM), FY25 Q3: $1.8B Revenue (TTM), FY25 Q4: $1.8B Revenue (TTM), FY26 Q1: $1.8B Revenue (TTM), FY26 Q2: $1.8B $1.8B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $2B
FY23 Q4 $1.9B
FY24 Q1 $1.9B
FY24 Q2 $1.9B
FY24 Q3 $1.9B
FY24 Q4 $1.8B
FY25 Q1 $1.8B
FY25 Q2 $1.8B
FY25 Q3 $1.8B
FY25 Q4 $1.8B
FY26 Q1 $1.8B
FY26 Q2 $1.8B
Revenue growth, TTM YoY Innospec Inc.
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 5.3% Revenue growth, TTM YoY, FY23 Q4: -0.8% Revenue growth, TTM YoY, FY24 Q1: -3.1% Revenue growth, TTM YoY, FY24 Q2: -5.9% Revenue growth, TTM YoY, FY24 Q3: -4.7% Revenue growth, TTM YoY, FY24 Q4: -5.3% Revenue growth, TTM YoY, FY25 Q1: -7.9% Revenue growth, TTM YoY, FY25 Q2: -5.5% Revenue growth, TTM YoY, FY25 Q3: -4.5% Revenue growth, TTM YoY, FY25 Q4: -3.7% Revenue growth, TTM YoY, FY26 Q1: 0.2% Revenue growth, TTM YoY, FY26 Q2: 2.9% 2.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 5.3%
FY23 Q4 -0.8%
FY24 Q1 -3.1%
FY24 Q2 -5.9%
FY24 Q3 -4.7%
FY24 Q4 -5.3%
FY25 Q1 -7.9%
FY25 Q2 -5.5%
FY25 Q3 -4.5%
FY25 Q4 -3.7%
FY26 Q1 0.2%
FY26 Q2 2.9%
Operating margin (TTM) Innospec Inc.
6% 7% 8% 9% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 8.3% Operating margin (TTM), FY23 Q4: 8.3% Operating margin (TTM), FY24 Q1: 8.8% Operating margin (TTM), FY24 Q2: 9.4% Operating margin (TTM), FY24 Q3: 9.7% Operating margin (TTM), FY24 Q4: 9.6% Operating margin (TTM), FY25 Q1: 9.5% Operating margin (TTM), FY25 Q2: 9.1% Operating margin (TTM), FY25 Q3: 6.9% Operating margin (TTM), FY25 Q4: 7.3% Operating margin (TTM), FY26 Q1: 6.9% Operating margin (TTM), FY26 Q2: 7.0% 7.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 8.3%
FY23 Q4 8.3%
FY24 Q1 8.8%
FY24 Q2 9.4%
FY24 Q3 9.7%
FY24 Q4 9.6%
FY25 Q1 9.5%
FY25 Q2 9.1%
FY25 Q3 6.9%
FY25 Q4 7.3%
FY26 Q1 6.9%
FY26 Q2 7.0%
FCF margin (TTM) Innospec Inc.
0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 7.9% FCF margin (TTM), FY23 Q4: 7.5% FCF margin (TTM), FY24 Q1: 10.9% FCF margin (TTM), FY24 Q2: 8.7% FCF margin (TTM), FY24 Q3: 9.9% FCF margin (TTM), FY24 Q4: 7.8% FCF margin (TTM), FY25 Q1: 5.2% FCF margin (TTM), FY25 Q2: 5.4% FCF margin (TTM), FY25 Q3: 3.1% FCF margin (TTM), FY25 Q4: 4.9% FCF margin (TTM), FY26 Q1: 4.3% FCF margin (TTM), FY26 Q2: 3.7% 3.7%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 7.9%
FY23 Q4 7.5%
FY24 Q1 10.9%
FY24 Q2 8.7%
FY24 Q3 9.9%
FY24 Q4 7.8%
FY25 Q1 5.2%
FY25 Q2 5.4%
FY25 Q3 3.1%
FY25 Q4 4.9%
FY26 Q1 4.3%
FY26 Q2 3.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Innospec took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.8B
  2. Cost of revenue $1.3B · 72.3%
  3. Gross profit $492M · 27.7%
  4. Research and development $51M · 2.9%
  5. Selling, general and admin $285M · 16.0%
  6. Other operating costs $26.8M · 1.5%
  7. Operating income $130M · 7.3%
  8. Income tax $21.5M · 1.2%
  9. Net income $117M · 6.6%

Shares of revenue. Source: Innospec's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 599 683 774 776 819 961 1,012 883 1,307 1,477 1,513 1,193 1,483 1,964 1,949 1,845 1,778 1,842
Gross profit 186 214 226 236 255 302 346 332 403 435 466 343 435 587 591 543 492 506
EBITDA 39 88 62 108 111 142 192 136 175 183 198 80 175 227 201 221 173 170
Operating income 21 72 47 97 91 113 156 98 125 134 150 34 132 187 162 178 130 129
Net income 6 74 47 67 78 84 120 81 62 85 112 29 93 133 139 36 117 122
Diluted EPS $0.26 $2.97 $1.92 $2.81 $3.22 $3.38 $4.86 $3.33 $2.52 $3.45 $4.54 $1.16 $3.75 $5.32 $5.56 $1.42 $4.67 $4.89
Growth (year on year)
Revenue — +14.2% +13.3% +0.3% +5.5% +17.4% +5.3% −12.7% +47.9% +13.0% +2.5% −21.2% +24.3% +32.4% −0.8% −5.3% −3.7% +2.9%
EBITDA — +124.0% −29.7% +75.3% +2.8% +27.6% +35.2% −28.8% +28.7% +4.4% +7.9% −59.6% +119.3% +30.1% −11.7% +10.2% −21.8% −17.9%
Operating income — +248.8% −34.6% +104.4% −6.1% +24.2% +38.9% −37.2% +27.3% +6.8% +12.3% −77.5% +292.0% +41.8% −13.7% +10.1% −27.2% −21.2%
Net income — — −36.1% +42.0% +16.3% +8.1% +42.1% −32.0% −24.0% +37.5% +32.0% −74.4% +224.4% +42.9% +4.6% −74.4% — —
Diluted EPS — — −35.4% +46.4% +14.6% +5.0% +43.8% −31.5% −24.3% +36.9% +31.6% −74.4% +223.3% +41.9% +4.5% −74.5% — —
Margins
Gross margin 31.1% 31.3% 29.2% 30.4% 31.2% 31.4% 34.2% 37.6% 30.9% 29.5% 30.8% 28.7% 29.3% 29.9% 30.3% 29.4% 27.7% 27.5%
EBITDA margin 6.5% 12.8% 8.0% 13.9% 13.6% 14.7% 18.9% 15.4% 13.4% 12.4% 13.1% 6.7% 11.8% 11.6% 10.3% 12.0% 9.7% 9.3%
Operating margin 3.5% 10.6% 6.1% 12.4% 11.1% 11.7% 15.4% 11.1% 9.6% 9.0% 9.9% 2.8% 8.9% 9.5% 8.3% 9.6% 7.3% 7.0%
Net margin 1.1% 10.8% 6.1% 8.6% 9.5% 8.8% 11.8% 9.2% 4.7% 5.8% 7.4% 2.4% 6.3% 6.8% 7.1% 1.9% 6.6% 6.6%
Free-cash-flow margin 13.4% 7.2% 3.6% 6.8% 6.1% 9.7% 9.9% 10.1% 4.5% 5.1% 8.7% 9.7% 3.6% 2.1% 7.5% 7.8% 4.9% 3.7%
Cash flow
Cash from operations 87 58 35 61 61 106 118 106 83 105 162 146 93 82 207 185 138 124
Capital spending 7 9 7 9 11 14 18 17 23 29 30 30 39 40 62 41 50 56
Free cash flow 80 49 28 53 50 93 101 89 59 76 132 116 54 42 145 143 88 69
Stock-based pay 2 1 3 3 3 3 4 3 4 5 7 6 4 7 8 9 8 11
Free cash flow after stock pay 79 49 25 50 48 90 97 86 55 71 125 110 50 35 137 135 80 58
Balance sheet
Cash 69 107 76 22 80 42 137 102 90 123 76 105 142 147 204 289 293 250
Total debt 0 47 35 30 148 139 132 269 218 208 59 0 0 0 0 0 0 0
Net debt (negative = net cash) −69 −60 −41 8 68 98 −5 167 128 85 −17 −105 −142 −147 −204 −289 −293 −250
Diluted shares 25m 25m 25m 24m 24m 25m 25m 24m 24m 25m 25m 25m 25m 25m 25m 25m 25m 25m
Returned to shareholders
Dividends 1 0 0 47 12 13 15 16 19 22 25 26 29 32 35 39 42 —
Buybacks 0 3 28 1 4 7 15 8 1 1 2 2 1 6 1 1 24 24
Total returned 1 3 28 48 16 20 30 24 20 23 27 28 30 38 36 40 66 24

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.8bn
Short-term assets $1.0bnLonger-term assets $822m
What it owes, and who funded it · $1.8bn
Short-term liabilities $368mLonger-term liabilities $127mShareholders' equity $1.3bn
  • Short-term assets cover short-term liabilities $1.0bn of assets due within a year against $368m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.0bn short-term assets against $127m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Innospec Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$24.1M
Returned to shareholders
35%
of free cash flow
Buybacks, last 3 fiscal years
$25.7M
Diluted share count
−1.1%
year over year
Total shareholder yield
1.0%
dividends 0.0% + buybacks 1.0% of market value
R&D spending
2.8%
of revenue
Sales & admin spending
16.5%
of revenue

Competitors: side by side with peers

Closest by revenue in specialty chemicals
Last 12 months unless stated IOSP ASH SXT KWR MTX SCL Median
Revenue, last 12 months $1.8bn $1.8bn $1.7bn $2.0bn $2.2bn $2.4bn $906m
Revenue growth, last 12 months 2.9% −1.4% 9.5% 8.7% 4.8% 7.6% 5.4%
Revenue growth, 3-year average −2.9% −7.2% 6.3% 0.9% 0.3% −1.9% 0.9%
Revenue growth, latest quarter 11.8% 7.3% 10.6% 10.3% 4.2% 15.0% 8.3%
Gross margin 27.5% 31.5% 35.1% 35.8% 23.9% 11.8% 28.8%
Operating margin 7.0% 7.4% 14.5% 7.6% −1.6% 0.8% 4.3%
Operating margin, 3-year average 8.5% −13.0% 12.7% 7.3% 4.8% 2.3% 5.5%
Net margin 6.6% 2.8% 9.7% 4.8% −3.1% −0.1% 0.8%
Cash from operations / revenue 6.7% 18.2% 6.9% 4.6% 10.8% 6.4% 6.9%
Free-cash-flow margin 3.7% 13.6% −1.0% 1.9% 5.9% 1.5% 4.3%
Free-cash-flow margin, 3-year average 5.9% 11.3% 3.3% 5.8% 6.3% 1.1% 5.1%
Stock pay / revenue 0.6% 1.0% 1.0% 0.7% — 0.3% 1.0%
Change in share count −1.1% −9.2% 0.5% −1.8% −2.2% −0.0% 0.1%

Median of all 42 companies we cover in specialty chemicals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

42 specialty chemicals companies
Measure Company Peer median Rank
Revenue growth Growth 2.9% 6.0% 25 of 42
Change in growth rate Growth +2.6pp +1.3pp 13 of 42
Gross margin Profitability 27.5% 31.5% 22 of 40
Operating margin Profitability 7.0% 3.8% 17 of 39
Net margin Profitability 6.6% 1.7% 10 of 42
Free-cash-flow margin Cash generation 3.7% 4.8% 22 of 42
Stock pay as % of revenue Cash generation 0.6% 1.0% 11 of 36
Change in share count Balance sheet -1.1% 0.0% 12 of 37

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue YoY
United States $952M ▼ 8.5%
United Kingdom $793M ▼ 3.7%
Rest of World $379M ▲ 31.2%

These categories overlap or exclude eliminations, so shares aren't shown.

From Innospec Inc.'s 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2B
Institutions reporting
279
Shares held vs prior quarter
▼ 0.3%
Positions opened / closed
39 / 27

Top buyers and sellers, Q2 2026: 143 institutions bought and 123 sold ; the biggest buyer was Blackrock, Inc (+502K shares) and the biggest seller Allspring Global Investments Holdings, LLC (−423K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $357M 4.4M 17.6% ▲ 13.0%
Allspring Global Investments Holdings, LLC $155M 1.9M 7.6% ▼ 18.3%
Vanguard Portfolio Management LLC $153M 1.9M 7.6% ▲ 1.3%
Dimensional Fund Advisors LP $106M 1.3M 5.2% ▲ 5.1%
Vanguard Capital Management LLC $90.2M 1.1M 4.5% ▼ 0.6%
State Street Corp $81.1M 996K 4.0% ▲ 3.3%
Nuveen, LLC $61.5M 756K 3.0% ▲ 17.5%
Geode Capital Management, LLC $54.3M 667K 2.7% ▲ 5.7%
Goldman Sachs Group Inc $53.9M 662K 2.7% ▲ 34.6%
Victory Capital Management Inc $53.7M 660K 2.7% ▼ 23.7%
Two Sigma Investments, LP $46.3M 569K 2.3% ▼ 4.1%
Assenagon Asset Management S.A. $44.4M 546K 2.2% ▲ 11.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Innospec Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $25,191 1 trade by 1 insider, last 12 months Insider sales History → $901,827 18 trades by 6 insiders · 0% under pre-set plans
Net ▼ $876,636 net selling
Insider Date Trade Shares Price Value
Jones David B. SVP, GC & CCO March 3, 2026 Sell 1,028 $75.64 $77,758
Cleminson Ian EVP & CFO February 27, 2026 Sell 2,380 $76.56 $182,213
Landless David Director February 27, 2026 Sell 594 $76.56 $45,477
Poccia Claudia Director February 27, 2026 Sell 119 $76.56 $9,111
Padfield Larry Director February 27, 2026 Sell 594 $76.56 $45,477
Blackmore Milton C Director February 27, 2026 Sell 594 $76.56 $45,477
Cleminson Ian EVP & CFO February 27, 2026 Sell 1,149 $76.30 $87,669
Cleminson Ian EVP & CFO February 27, 2026 Sell 1,231 $76.79 $94,528
Landless David Director February 27, 2026 Sell 307 $76.79 $23,575
Landless David Director February 27, 2026 Sell 287 $76.30 $21,898
Poccia Claudia Director February 27, 2026 Sell 62 $76.79 $4,761
Poccia Claudia Director February 27, 2026 Sell 57 $76.30 $4,349

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 8, 2026
  • February 18, 2026
  • November 5, 2025
  • August 6, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Innospec Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Innospec Inc. in brief

What does Innospec Inc. do?
Innospec Inc. is a US-listed company in the specialty chemicals industry. Its financial year ends in December.
What is Innospec Inc.'s stock ticker?
Innospec Inc. trades under the ticker IOSP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Innospec Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Innospec Inc. reported revenue of $1.8B, 2.9% higher than a year earlier, according to its SEC filings.
What is Innospec Inc.'s free cash flow?
Innospec Inc.'s free-cash-flow margin is 3.7% of revenue over the trailing twelve months, ranking 22 of the 42 specialty chemicals companies we cover.
What is Innospec Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Innospec Inc.'s free cash flow after stock-based pay gives ~$79 per share in the base case, and ~$62–$100 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Innospec Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Allspring Global Investments Holdings, LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Innospec Inc. buying back stock, and does it pay a dividend?
Innospec Inc. spent $24.1M on share repurchases over the trailing twelve months, and its diluted share count fell 1.1% over the year.
What is Innospec Inc.'s market cap?
On November 2, 2026, Innospec Inc.'s market capitalisation was about $2.5B, with a price-to-earnings ratio of 20.4 and net debt of -$250M. Market figures come from third-party market data and may be delayed.
Who are Innospec Inc.'s competitors?
In our Specialty Chemicals peer group, the companies closest to Innospec Inc. are Ashland Inc., Sensient Technologies Corp, Quaker Chemical Corp, Minerals Technologies Inc and Stepan Co. The side-by-side comparison below sets their revenue, margins and growth against Innospec Inc.'s.
Are insiders buying or selling Innospec Inc. stock?
Over the last 12 months, Innospec Inc.'s directors and officers reported 1 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Innospec Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Innospec Inc. announces its own schedule.